Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06315426 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 25, 2025 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 2024 to May 2025v3 Show 5 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 90 to confirmed 240
    • Study sites: 0 to 15
    • Study completion date: Dec 2024 to Oct 2025
    • Start date changed from estimate of Mar 2024 to Mar 24, 2024
  2. Primary endpoint revised
    • Secondary endpoints revised (8)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Trial Details
NCT Number NCT06315426
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Allergic Rhinitis
Related terms Rhinitis, Allergic
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov